Syngene International Ltd

Stage 1 · Basing · week 1

As of 20 Nov 2026, Syngene International is in Stage 1, the basing phase, now in its first week (since 17 Nov 2026). It closed at ₹452, 31.6% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More about the company

₹451.7
Close, 20 Nov 2026
+3.28% on the day
₹18,154 Cr · Mid cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dLabs & Life Sciences Services 33.3%0.0 pts

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

RS rank

Edge

—

SYNGENE is basing for in its first week, above its 50-day average; it has not started an uptrend yet.

Its relative strength is 23 of 99, below the middle among NSE stocks over the past year. Labs & Life Sciences Services ranks 70 of 106 industries by the strength of its stocks.

Is SYNGENE early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S4 17w
S2 22w
S4 23w
S4 16w
S4 17w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 8w → S3 9w → S4 6w → S1 7w → S4 17w → S1 2w → S2 22w → S3 7w → S4 23w → S1 10w → S4 11w → S1 4w → S4 16w → S1 9w → S4 17w → S1 1w current
Total tracked: 168 weeks across 16 stage runs.

SYNGENE among Labs & Life Sciences Services4th of 6 by relative strength

All 6 →
Stocks in Labs & Life Sciences Services ranked by relative strength, with stage and one-month change
#StockStageRS1M
1DIVISLABStage 2 · wk 2693+21.7%
2AARTIPHARMStage 2 · wk 1384+17.5%
3VIMTALABSStage 3 · wk 530−4.3%
4SYNGENEStage 1 · wk 123+20.0%
5BROOKSStage 1 · wk 316+10.6%
6DCALStage 4 · wk 145−18.7%
vs 52W High
-31.6%
₹346 lo₹660.4 hi
31.6% below 52W high, far from high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 1
1w13w26w
Week 1, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
7.8%
200 DMA: ₹419 · sloping down
The stock has reclaimed its 200-day average while it bases. Holding above the line is one of the things a Stage 2 advance needs.
Rel Volume
1.72x
vs 50-day avg
Volume ran well above average on an up day. Inside a base, that kind of interest often comes before a breakout, if it follows through.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+20.0%
3M
+13.8%
6M
-3.1%
YTD
-30.6%
1Y
-31.8%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Labs & Life Sciences Services
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
+20.9%
3M return
+27.9%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Labs & Life Sciences Services Stage 2 →

Mutual fund holdings

Held by 80 mutual funds in portfolios to October 2026: 49 active funds and 31 index funds and ETFs.

In October, among active funds: 11 increased, 2 opened a new position, 2 reduced and 1 exited.

13 increased or opened3 reduced or exited
All 80 funds, the 1 that exited, and what each did in October

Mutual funds holding SYNGENE: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 30 Jul 2024
Recent Stage Timeline
2026-11-20S1
Wk 1 · Vol 1.72x
2026-11-19S1
Wk 1 · Vol 0.15x
2026-11-18S1
Wk 1 · Vol 0.37x
2026-11-17S14→1
Wk 1 · Vol 0.28x
2026-11-16S4
Wk 17 · Vol 1.32x
2026-11-13S4
Wk 17 · Vol 0.45x
2026-11-12S4
Wk 16 · Vol 0.37x
2026-11-11S4
Wk 16 · Vol 0.91x
2026-11-09S4
Wk 16 · Vol 0.89x
2026-11-06S4
Wk 16 · Vol 0.72x
2026-11-05S4
Wk 16 · Vol 0.43x
2026-11-04S4
Wk 15 · Vol 0.58x
Moving averages & range
50 DMA
₹392
200 DMA
₹419
52W High
₹660.4
52W Low
₹346
5D Low
₹434.4
Resistance levels (recent highs)
20d High
₹451.7
60d High
₹451.7
120d High
₹458.6
250d High
₹660.4
Next resistance
+1.5%
to 120d High
P/E (TTM)
97.8
Forward 44.2
Earnings Growth (YoY)
-52.1%
Revenue -8.6%
ROE
+3.9%
Profit margin +5.3%
Dividend Yield
0.28%
P/B 3.7

Syngene International: quick answers

What stage is Syngene International in?

As of 20 Nov 2026, Syngene International (SYNGENE) is in Stage 1, the basing phase. It entered Stage 1 on 17 Nov 2026 and is in its first week there. What the four stages mean

Is Syngene International in an uptrend?

Not yet. Syngene International is in Stage 1, a base that can come before an uptrend. It trades 7.8% above its 200-day average, which is falling.

How far is Syngene International from its 52-week high?

Syngene International closed at ₹452 on 20 Nov 2026, 31.6% below its 52-week high of ₹660. Its 52-week low is ₹346.

How has Syngene International performed over the past year?

As of 20 Nov 2026, Syngene International is down 31.8% over the past year and down 30.6% so far in 2026.

Which sector and industry is Syngene International in?

Syngene International is in the Labs & Life Sciences Services industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Labs & Life Sciences Services

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.